Biotech, RNA Interference, Finance
AVI Biopharma Hires New CFO, President On His Way Out
Luke Timmerman 7/28/08
AVI Biopharma, (NASDAQ: AVII) a Portland, OR-based developer of drugs using RNA interference technology, said today it has hired J. David Boyle II as chief financial officer, while current CFO Mark Webber will become general manager of finance and administration. Alan Timmins, the current president and chief operating officer, will leave the company and his duties as president will be assumed by CEO Leslie Hudson.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
